DEFA14A: Keros Therapeutics Secures Key Proxy Advisor Endorsement Ahead of Annual Meeting

Leading independent proxy advisory firm Glass Lewis & Co. has recommended Keros Therapeutics stockholders vote FOR all three of the company's director nominees at the upcoming Annual Meeting, countering an activist campaign by ADAR1 Capital Management.

Summary

• Keros Therapeutics announced that Glass Lewis & Co. recommended stockholders vote FOR all three of its director nominees for the Annual Meeting of Stockholders scheduled for June 4, 2025.
• Glass Lewis recognized the value of Keros's directors and supported the Board's actions taken to date to maximize stockholder value.
• Glass Lewis stated that the magnitude of the company's 73% one-day share price collapse stemmed primarily from inherent clinical development risk, specifically a setback in the TROPOS clinical trial, rather than board-level mismanagement.
• Glass Lewis found no compelling evidence that directors Gray or Seth played a disproportionate role in the company's missteps or failed to fulfill their core duties.
• Glass Lewis supported the Board's decision to retain flexibility through a formal strategic review, led by a special committee of independent, disinterested directors, as a reasonable and measured approach.
• Glass Lewis viewed the adoption of the Rights Plan as reasonably timed and narrowly scoped, not an entrenchment device or an act of bad faith.
• Keros refuted ADAR1 Capital Management's claims regarding Institutional Shareholder Services (ISS) recommendation, stating ISS's report was based on standard voting guidelines for uncontested director elections and did not address ADAR1's allegations.
• Keros emphasized its Board's composition of nine directors (eight independent, including four stockholder representatives) and their diverse experience across the biotechnology industry, including drug development, commercialization, capital allocation, and M&A.

Sentiment

Score: 7

Explanation: The document presents a strong positive development for Keros Therapeutics, as a leading independent proxy advisory firm, Glass Lewis, has sided with the company's board and management against an activist investor. This endorsement validates the board's strategic review process and refutes claims of mismanagement, which is a significant win in a proxy contest. However, the underlying negative of a 73% share price collapse due to clinical trial failure remains a major concern, preventing a higher score.

Positives

• Glass Lewis & Co., a leading independent proxy advisory firm, recommended stockholders vote FOR all three of Keros's highly qualified director nominees.
• Glass Lewis recognized the value and experience that Keros's directors bring to the Board and supported the Board and management team's actions to maximize stockholder value.
• Glass Lewis attributed the 73% share price collapse primarily to inherent clinical development risk from the TROPOS clinical trial setback, rather than board-level mismanagement.
• Glass Lewis found no credible evidence suggesting directors Gray or Seth mismanaged the trial or failed to fulfill their core duties.
• Glass Lewis supported the Board's decision to conduct a formal strategic review, led by a special committee of independent, disinterested directors, as a reasonable and measured approach.
• Glass Lewis viewed the adoption of the Rights Plan as reasonably timed and narrowly scoped, not reflecting aggressive features often seen in contested situations or suggesting bad faith.
• The Keros Board comprises nine directors, eight of whom are independent, including four representatives of Keros stockholders (two from Pontifax, the second-largest stockholder).
• The Board possesses diverse perspectives and significant experience across the biotechnology industry, including drug development and commercialization, capital allocation, M&A, and business development.

Negatives

• The company experienced a significant 73% one-day share price decline due to a setback in the TROPOS clinical trial.
• ADAR1 Capital Management, LLC is conducting an aggressive campaign to oppose two highly qualified members of the Board, which Keros characterizes as self-serving and value-destructive.
• ADAR1's claims regarding ISS's voting recommendation were deemed false and misleading by Keros.

Risks

• Uncertainty regarding whether the objectives of the strategic alternative review process will be achieved.
• Risks related to the terms, structure, benefits, and costs of any strategic transaction.
• Uncertainty regarding the timing of any transaction and whether any transaction will be consummated at all.
• The strategic alternatives review and its announcement could adversely affect the company's ability to retain and hire key personnel and maintain relationships with partners, suppliers, employees, stockholders, and other business relationships.
• The strategic alternatives review could divert the attention and time of the company's management.
• Risk of unexpected costs or expenses resulting from the review.
• Risk of litigation relating to the review.
• Keros's limited operating history and historical losses.
• Keros's ability to raise additional funding to complete the development and any commercialization of its product candidates.
• Keros's dependence on the success of its product candidates, cibotercept, KER-065, and elritercept.
• Potential delays in initiating, enrolling, or completing any clinical trials.
• Competition from third parties that are developing products for similar uses.
• Risk that circumstances surrounding or leading up to the 2025 Annual Meeting may change.
• Keros's ability to obtain, maintain, and protect its intellectual property.
• Keros's dependence on third parties in connection with manufacturing, clinical trials, and preclinical studies.

Future Outlook

Keros's Board remains focused on successfully completing the strategic alternatives review process, which is ongoing, with the aim of maximizing stockholder value. The company continues to develop its product candidates, cibotercept, KER-065, and elritercept, for various disorders linked to dysfunctional signaling of the TGF-beta family of proteins.

Management Comments

• "We are pleased that Glass Lewis recognizes the value that our directors bring to the Board and understands that the Board and management teams actions taken to date to maximize stockholder value are reasonable and measured."
• "Our Board is intentionally built, comprised of experienced individuals, many of whom directly represent stockholders, and will continue to focus on evaluating alternatives in the best interests of the Company and all stockholders."
• "We continue to believe that the most constructive course of action for stockholders at this pivotal stage in our strategic alternatives review is to remain focused on effectively running the company and a comprehensive process rather than being sidetracked by a self-serving and value-destructive campaign."
• "The Keros Board comprises nine directors, all of whom are independent except for the Companys CEO. This includes four representatives of Keros stockholders, two of whom are representatives of Pontifax, the Companys second largest stockholder."
• "Collectively, the Board represents diverse perspectives and brings significant experience across the biotechnology industry, including drug development and commercialization, capital allocation, M&A and business development."
• "In short, Keros has the right Board to oversee the ongoing strategic review process to maximize stockholder value and execute on the ultimate outcome of that process."
• "We have always made, and will continue to make, decisions that we believe are in the best interests of the Company and ALL stockholders."
• "We strongly urge you to vote FOR each of Keros three director nominees, Mary Ann Gray, Ph.D., Ran Nussbaum and Alpna Seth, Ph.D."

Industry Context

The document highlights the inherent volatility and binary nature of clinical-stage biotech investing, where a company's valuation can be heavily reliant on a lead product candidate that has not yet been clinically de-risked. It also touches upon the increasing trend of activist investor campaigns in the biotech sector, often triggered by significant share price declines or perceived mismanagement, and the critical role of independent proxy advisory firms in influencing shareholder votes during such contests.

Comparison to Industry Standards

• The document implicitly compares Keros's situation to typical clinical-stage biotech companies, noting the "volatile and often binary nature of clinical-stage biotech investing" and the reliance on lead product candidates.
• It references "more aggressive features often seen in contested situations" when discussing shareholder rights plans, implying Keros's plan is less aggressive than some industry precedents.
• It contrasts ISS's standard voting guidelines for uncontested director elections with the "special situations team" that typically evaluates activist campaigns, suggesting a common industry practice for proxy advisor analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the proxy contest outcome, the ongoing strategic review process, and the potential for value maximization or destruction. The prior 73% share price decline has already significantly impacted their investment value.
• Employees: Potential impact on retention and hiring of key personnel due to the strategic alternatives review process.
• Partners/Suppliers: Potential impact on relationships due to the strategic alternatives review process.
• Management: Attention and time may be diverted by the strategic alternatives review and the proxy contest.

Next Steps

• Stockholders are strongly urged to vote FOR Keros's three director nominees (Mary Ann Gray, Ph.D., Ran Nussbaum, and Alpna Seth, Ph.D.) by telephone, internet, or mail.
• The Annual Meeting of Stockholders is scheduled for June 4, 2025.
• The Board remains focused on successfully completing the strategic alternatives review process.

Key Dates

Recommendation

Keywords

Keros Therapeutics, KROS, Glass Lewis, Proxy Statement, Annual Meeting, Director Nominees, Shareholder Vote, ADAR1 Capital Management, Proxy Fight, Corporate Governance, Strategic Review, Clinical-stage biopharmaceutical, TGF-beta, Cibotercept, KER-065, Elritercept, TROPOS clinical trial, Share price decline, Biotech investing, Shareholder rights plan